Compare FLOC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | ABUS |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | 1281 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.8M | 929.6M |
| IPO Year | N/A | 2008 |
| Metric | FLOC | ABUS |
|---|---|---|
| Price | $24.82 | $4.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $28.50 | $5.00 |
| AVG Volume (30 Days) | 629.1K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $8.59 | $239.71 |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $14.03 | $3.04 |
| 52 Week High | $25.30 | $5.10 |
| Indicator | FLOC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 52.68 |
| Support Level | $15.04 | $4.42 |
| Resistance Level | N/A | $4.64 |
| Average True Range (ATR) | 0.94 | 0.20 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 84.43 | 56.76 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.